



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/666,430
Filing Date	September 21, 2000
First Named Inventor	Rea et al.
Group Art Unit	1644
Examiner Name	G. Ewoldt
Attorney Docket Number	3157-4205 IUS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	ADIS DRUG INFORMATION 01-1010 (American Society of Hospital Pharmacists, Inc., 1991).	
	2	Metabolic Disorders of the Oral Cavity 1044-46 (Garland Publishing, 1989).	
	3	KEMINGTON'S PHARMACEUTICAL SCIENCES 938-72 (Mack Publishing Company, Alfonso R. Gennaro ed., 1986).	
	4	Fujikawa v. Wattanasin, 93 F.3d 1559, (Fed. Cir., 1996).	
	5	DICTIONARY OF GENETICS 14, 552 (Oxford University Press, 1997).	
	12	Web: Glucocorticoids -- Disease Mechanism II: Inflammation (last modified 5-7-03) <http://cg.stanford.edu/group/hopes/cgi-bin/pfind.pl?pubname=/group/hopes/treatmts/antiinflam13.html>.	
	A	Genetics and Molecular Immunology 115-17 (W.B. Saunders Company, 1997).	
	B	Human Physiology: The Mechanisms of Body Function 599-610 (McGraw Hill, Inc., 4th Ed. 1985).	
	C	Donaldson Company, Inc., 29 U.S.P.Q. 2d 1845 (Fed. Cir., 1994).	

Examiner Signature	<i>[Signature]</i> 7/20/05	Date Considered	
-----------------------	----------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.